Treatment and diagnosis of toxoplasma-associated disease
AssigneeThe Johns Hopkins University
InventorsJianchun Xiao, Raphael P. Viscidi, Robert H. Yolken
Life of this patent
Estimating the term…
Abstract
Methods of predicting risk of subsequent diseases following Toxoplasma infection in multiple at-risk populations including patients with ocular toxoplasmosis or congenital toxoplasmosis, transplant recipients and other immunosuppressed patients with prior exposure to toxoplasma. The methods include the use of synthetic modified Toxoplasma cyst peptides.
Claims23
A method of diagnosing Toxoplasma-associated disease in a subject comprising:
- obtaining a biological sample from the subject;
- culturing the biological sample with a modified Toxoplasma cyst peptide;
- measuring the amount of antibodies binding to the modified Toxoplasma cyst peptide;
- and
- diagnosing Toxoplasma-associated disease in the subject.
16-25. (canceled)
A synthetic peptide wherein the synthetic peptide comprises an amino acid sequence having at least a 50% sequence identity to
- (SEQ ID NO:
- 1)
- EKQLRRVEPEHEDNTRVEAR/P/RALLEAKTKELVEPTSKEAEEAR
- QILAEQAA.
30-31. (canceled)
The synthetic peptide of claim 30, wherein the peptide comprises an amino acid sequence having at least an 80%, 85%, 90%, 95%, 98% or 99% sequence identity to
- (SEQ ID NO:
- 2)
- YENSEDVAVPSDSASTP/DCEEQQEQGDTTLSDHDFHSGGTEQEGL
- PETEVAHQHETEEQ.
(canceled)
Dependencies are inferred from the claim text.